AbstractObjective To analyze the outcomes and prognostic factors in patients with esophageal cancer after concurrent chemoradiotherapy. Methods A total of 135 patients with esophageal squamous cell carcinoma were enrolled in the clinical study from January 2008 to June 2015. The patients were treated with two-dimensional radiotherapy (56 patients) or three-dimensional radiotherapy (79 patients). The radiotherapy was delivered at a total dose of 60-64 Gy (1.8-2.0 Gy per fraction). The concurrent chemotherapy regimen consisted of fluorouracil plus cisplatin or paclitaxel plus cisplatin and was performed on days 1 and day 29 of radiotherapy. The Kaplan-Meier method was used to calculate overall survival (OS) and progression-free survival (PFS) rates, the log-rank test was used for survival difference analysis andunivariate prognostic analysis, and the Cox model was used for multivariate prognostic analysis. Results The 1-, 3-, and 5-year sample sizes were 96,31,16, respectively. The 1-, 3-, and 5-year OS rates were 74.0%, 39.0%, and 28.6%, respectively;the median OS time was 25 months. The 1-, 3-, and 5-year PFS rates were 57.3%, 27.3%, and 16.6%, respectively;the median PFS time was 15 months. The univariate analysis indicated that clinical stage, radiotherapy method, and M stage were prognostic factors for OS and PFS (P=0.006, 0.000, and 0.032;P=0.017, 0.004, and 0.000). The multivariate analysis showed that clinical stage and radiotherapy method were independent prognostic factors for OS and PFS (P=0.006 and 0.000;P=0.033 and 0.023). Conclusions For non-surgical treatment of patients with esophageal cancer, concurrent chemoradiotherapy is a preferred strategy and has proven to be effective and tolerable.
Wang Xiushen,Zhang Xiqian,Liu Xiao et al. Analysis of outcomes and prognostic factors in patients with esophageal cancer after concurrent chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2017, 26(4): 400-404.
Wang Xiushen,Zhang Xiqian,Liu Xiao et al. Analysis of outcomes and prognostic factors in patients with esophageal cancer after concurrent chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2017, 26(4): 400-404.
[1] 殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].4版.北京:中国协和医科大学出版社,2008:546-573. Yin WB,Yu ZH,Xu GZ,et al. Radiation oncology[M].4th ed. Beijing:Peking Union Medical College Press,2008:546-573 [2] Cooper JS,Guo MD,Herskovic A,et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01)[J].JAMA,1999,281(17):1623-1627.DOI:10.1001/jama.281.17.1623 [3] Han JH,Zhu WG,Yu CH,et al. Clinical study of concurrent chemoradiotherapy or radiotherapy alone for esophageal cancer patients with positive lymph node metastasis[J].Tumori,2012,98(1):60-65.DOI:10.1700/1053.11501 [4] Shirai K,Tamaki Y,Kitamoto Y,et al. Comparison of chemoradiotherapy with radiotherapy alone in patients with esophageal adenocarcinoma[J].J Radiat Res,2011,52(3):264-269.DOI:10.1269/jrr.10166 [5] Suntharalingam M,Moughan J,Coia LR,et al. The national practice for patients receiving radiation therapy for carcinoma of the esophagus:results of the 1996-1999 Patterns of Care Study[J].Int J Radiat Oncol Biol Phys,2003,56(4):981-987.DOI:10.1016/S0360-3016(03)00256-6 [6] Sobin LH,Wittekind C.TNM classification of malignant tumours[J].6th ed. New York:Wildy-Liss,2002 [7] 蒋杰,王奇峰,肖泽芬,等.132例食管癌三维适形放疗的疗效分析[J].中华放射肿瘤学杂志,2009,18(1):47-51.DOI:10.3760/cma.j.issn.1004-4221.2009.01.047. Jiang J,Wang QF,Xiao ZF,et al. Efficacy of three-dimensional conformal radiotherapy for 132 patients with esophageal carcinoma[J].Chin J Radiat Oncol,2009,18(1):47-51.DOI:10.3760/cma.j.issn.1004-4221.2009.01.047 [8] Worni M,Martin J,Gloor B,et al. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008[J].J Am Coll Surg,2012,215(5):643-651.DOI:10.1016/j.jamcollsurg.2012.07.006 [9] Kato K,Muro K,Minashi K,et al. Phase Ⅱ study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage Ⅱ–Ⅲ esophageal squamous cell carcinoma:JCOG trial (JCOG 9906)[J].Int J Radiat Oncol Biol Phys,2011,81(3):684-690.DOI:10.1016/j.ijrobp.2010.06.033. [10] 孔洁,李晓宁,韩春,等.792例食管癌三维技术放疗的疗效分析[J].中华放射肿瘤学杂志,2012,21(5):421-424.DOI:10.3760/cma.j.issn.1004-4221.2012.05.007. Kong J,Li XN,Han C,et al. Treatment outcomes of 792 cases of esophageal carcinoma patients treated with three-dimensional radiotherapy[J].Chin J Radiat Oncol,2012,21(5):421-424.DOI:10.3760/cma.j.issn.1004-4221.2012.05.007. [11] 谭立君,刘晓,肖泽芬,等.592例食管癌3DRT的预后分析[J].中华放射肿瘤学杂志,2015,24(1):10-15.DOI:10.3760/cma.j.issn.1004-4221.2015.01.004. Tan LJ,Liu X,Xiao ZF,et al. Analysis of outcomes and prognostic factors in 592 esophageal cancer patients treated with three-dimensional radiotherapy[J].Chin J Radiat Oncol,2015,24(1):10-15.DOI:10.3760/cma.j.issn.1004-4221.2015.01.004. [12] Lin SH,Wang L,Myles B,et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy for esophageal cancer[J].Int J Radiat Oncol Biol Phys,2012,84(5):1078-1085.DOI:10.1016/j.ijrobp.2012.02.015. [13] 肖泽芬,章众,张红志,等.用三维TPS评估食管癌常规放射治疗中肿瘤剂量的分布[J].中华放射肿瘤学杂志,2004,13(4):273-277.DOI:10.3760/j.issn:1004-4221.2004.04.008. Xiao ZF,Zhang Z,Zhang HZ,et al. Assessment of tumor dose distribution in three dimensional conformal radiotherapy treatment planning system for esophageal cancer[J].Chin J Radiat Oncol,2004,13(4):273-277.DOI:10.3760/j.issn:1004-4221.2004.04.008. [14] Bedford JL,Khoo VS,Dearnaley DP,et al. Improved methods for adding transaxial two-dimensional margins to the superior and inferior regions of a clinical target volume[J].Med Dosim,1999,24(3):169-175.DOI:10.1016/S0958-3947(99)00011-4. [15] 王澜,韩春,祝淑钗,等.食管癌常规照射与三维适形放疗 的剂量学研究[J].中华放射肿瘤学杂志,2006,15(3):176-180.DOI:10.3760/j.issn:1004-4221.2006.03.005. Wang L,Han C,Zhu SC,et al. Dosimetry study on conventional and three dimensional conformal radiotherapy for esophageal cancer[J].Chin J Radiat Oncol,2006,15(3):176-180.DOI:10.3760/j.issn:1004-4221.2006.03.005. [16] Ahmad M,Nath R.Three-dimensional radiotherapy of head and neck and esophageal carcinomas:a monoisocentric treatment technique to achieve improved dose distributions[J].Int J Cancer,2001,96(1):55-65.DOI:10.1002/1097-0215(20010220) 96:1<55::AID-IJC6>3.0.CO;2-#. [17] 刘晓,王贵齐,贺舜,等.探讨非手术食管癌临床分期有效性与预测预后价值[J].中华放射肿瘤学杂志,2014,23(1):17-22.DOI:10.3760/cma.j.issn.1004-4221.2014.01.005. Liu X,Wang GQ,He S,et al. Efficacy and predictive value of clinical stage in non-surgical patients with esophageal cancer[J].Chin J Radiat Oncol,2014,23(1):17-22.DOI:10.3760/cma.j.issn.1004-4221.2014.01.005. [18] van Vliet EPM,Heijenbrok-Kal MH,Hunink MGM,et al. Staging investigations for oesophageal cancer:a meta-analysis[J].Br J Cancer,2008,98(3):547-557.DOI:10.1038/sj.bjc.6604200. [19] Kayani B,Zacharakis E,Ahmed K,et al. Lymph node metastases and prognosis in oesophageal carcinoma–a systematic review[J].Eur J Surg Oncol (EJSO),2011,37(9):747-753.DOI:10.1016/j.ejso.2011.06.018. [20] Pennathur A,Gibson MK,Jobe BA,et al. Oesophageal carcinoma[J].Lancet,2013,381(9864):400-412.DOI:10.1016/S0140-6736(12)60643-6. [21] Rice TW,Rusch VW,Ishwaran H,et al. Cancer of the esophagus and esophagogastric junction[J].Cancer,2010,116(16):3763-3773.DOI:10.1002/cncr.25146. [22] 谭立君,刘江涛,肖泽芬.食管癌UICC TNM分期的发展及临床应用[J].中华放射肿瘤学杂志,2014,23(4):365-369.DOI:10.3760/cma.j.issn.1004-4221.2014.04.024. Tan LJ,Liu JT,Xiao ZF.The development and clinical application of UICC TNM staging of esophageal carcinoma[J].Chin J Radit Oncol,2014,23(4):365-369.DOI:10.3760/cma.j.issn.1004-4221.2014.04.024. [23] 中国非手术治疗食管癌临床分期专家小组.非手术治疗食管癌的临床分期标准(草案)[J].中华放射肿瘤学杂志,2010,19(3):179-180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001.Expert group on clinical staging of non operative treatment of esophageal cancer in China. Clinical staging criteria for non operative treatment of esophageal cancer (Draft)[J].Chin J Radit Oncol,2010,19(3):179-180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001. [24] 祝淑钗,么伟楠,李娟,等.食管癌非手术治疗临床分期新标准的对比研究[J].中华放射肿瘤学杂志,2016,25(2):109-113.DOI:10.3760/cma.j.issn.1004-4221.2016.02.005. Zhu ZC,Yao WN,Li J,et al. A comparative study of new clinical staging systems for esophageal carcinoma treated with non-surgical therapy[J].Chin J Radiat Oncol,2016,25(2):109-113.DOI:10.3760/cma.j.issn.1004-4221.2016.02.005. [25] Zhao KL,Ma JB,Liu G,et al. Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma:is elective nodal irradiation necessary?[J].Int J Radiat Oncol Biol Phys,2010,76(2):446-451.DOI:10.1016/j.ijrobp.2009.02.078. [26] 沈文斌,祝淑钗,高红梅,等.可手术切除食管癌单纯三维适形放疗失败原因分析[J].中华放射肿瘤学杂志,2013,22(3):205-208.DOI:10.3760/cma.j.issn.1004-4221.2013.03.009. Shen WB,Zhu SC,Gao HM,et al. Analysis of failure patterns of three-dimensional conformal radiotherapy alone in resectable esophageal cancer[J].Chin J Radiat Oncol,2013,22(3):205-208.DOI:10.3760/cma.j.issn.1004-4221.2013.03.009.
2017, Vol. 26 
